Identification and characterisation of peptide binding motifs of six autoimmune disease-associated human leukocyte antigen-class I molecules including HLA-B*39:06

Tissue Antigens

Volumn 84, Issue 4, 2014, Pages 378-388

  Eichmann, M ^a   de Ru, A ^b   van Veelen, P A ^b   Peakman, M ^a   Kronenberg Versteeg, D ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Antigen presentation; Binding motif; Immunopeptidome; Mass spectrometry

Indexed keywords

HLA A ANTIGEN; HLA B ANTIGEN;

ALLELE; CD8+ T LYMPHOCYTE; GENETICS; HUMAN; IMMUNOLOGY; INSULIN DEPENDENT DIABETES MELLITUS; K562 CELL LINE; PROTEIN MOTIF; PROTEIN TERTIARY STRUCTURE; TRANSFORMED CELL LINE;

ALLELES; AMINO ACID MOTIFS; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TRANSFORMED; DIABETES MELLITUS, TYPE 1; HLA-A ANTIGENS; HLA-B ANTIGENS; HUMANS; K562 CELLS; PROTEIN STRUCTURE, TERTIARY;

EID: 84907931326     PISSN: 00012815     EISSN: 13990039     Source Type: Journal    
DOI: 10.1111/tan.12413     Document Type: Article

References (45)

1. Vyas JM, Van der Veen AG, Ploegh HL. The known unknowns of antigen processing and presentation. Nat Rev Immunol 2008: 8: 607-18.
2. Neefjes J, Jongsma ML, Paul P, Bakke O. Towards a systems understanding of MHC class I and MHC class II antigen presentation. Nat Rev Immunol 2011: 11: 823-36.
3. Stevanovic S, Lemmel C, Hantschel M, Eberle U. Generating data for databases - the peptide repertoire of HLA molecules. Novartis Foundation Symposium 2003: 254: 143-55 discussion 55-64, 216-22, 50-2.
4. Guo HC, Jardetzky TS, Garrett TP, Lane WS, Strominger JL, Wiley DC. Different length peptides bind to HLA-Aw68 similarly at their ends but bulge out in the middle. Nature 1992: 360: 364-6.
5. Theodossis A, Guillonneau C, Welland A et al. Constraints within major histocompatibility complex class I restricted peptides: presentation and consequences for T-cell recognition. Proc Natl Acad Sci U S A 2010: 107: 5534-9.
6. Falk K, Rotzschke O, Stevanovic S, Jung G, Rammensee HG. Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature 1991: 351: 290-6.
7. Lundegaard C, Lund O, Kesmir C, Brunak S, Nielsen M. Modeling the adaptive immune system: predictions and simulations. Bioinformatics 2007: 23: 3265-75.
8. Rammensee H, Bachmann J, Emmerich NP, Bachor OA, Stevanovic S. SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 1999: 50: 213-9.
9. Parker KC, Bednarek MA, Coligan JE. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J Immunol 1994: 152: 163-75.
10. Erup Larsen M, Kloverpris H, Stryhn A et al. HLA restrictor - a tool for patient-specific predictions of HLA restriction elements and optimal epitopes within peptides. Immunogenetics 2011: 63: 43-55.
11. Valdes AM, Erlich HA, Noble JA. Human leukocyte antigen class I B and C loci contribute to Type 1 Diabetes (T1D) susceptibility and age at T1D onset. Hum Immunol 2005: 66: 301-13.
12. Gonzalez-Galarza FF, Christmas S, Middleton D, Jones AR. Allele frequency net: a database and online repository for immune gene frequencies in worldwide populations. Nucleic Acids Res 2011: 39: D913-9.
13. Skowera A, Ellis RJ, Varela-Calvino R et al. CTLs are targeted to kill beta cells in patients with type 1 diabetes through recognition of a glucose-regulated preproinsulin epitope. J Clin Invest 2008: 118: 3390-402.
14. Stepniak D, Wiesner M, de Ru AH et al. Large-scale characterization of natural ligands explains the unique gluten-binding properties of HLA-DQ2. J Immunol 2008: 180: 3268-78.
15. Meiring HD, van der Heeft E, ten Hove GJ, de Jong APJM. Nanoscale LC-MS(n): technical design and applications to peptide and protein analysis. J Sep Sci 2002: 25: 557-68.
16. Colaert N, Helsens K, Martens L, Vandekerckhove J, Gevaert K. Improved visualization of protein consensus sequences by iceLogo. Nat Methods 2009: 6: 786-7.
17. Consortium TU. Reorganizing the protein space at the Universal Protein Resource (UniProt). Nucleic Acids Res 2012: 40: D71-5.
18. Thomas PD, Kejariwal A, Campbell MJ et al. PANTHER: a browsable database of gene products organized by biological function, using curated protein family and subfamily classification. Nucleic Acids Res 2003: 31: 334-41.
19. Hoof I, Peters B, Sidney J et al. NetMHCpan, a method for MHC class I binding prediction beyond humans. Immunogenetics 2009: 61: 1-13.
20. Nielsen M, Lundegaard C, Blicher T et al. NetMHCpan, a method for quantitative predictions of peptide binding to any HLA-A and -B locus protein of known sequence. PLoS One 2007: 2: e796.
21. Sidney J, Peters B, Frahm N, Brander C, Sette A. HLA class I supertypes: a revised and updated classification. BMC Immunol 2008: 9: 1.
22. Rammensee HG, Falk K, Rotzschke O. Peptides naturally presented by MHC class I molecules. Annu Rev Immunol 1993: 11: 213-44.
23. Tynan FE, Burrows SR, Buckle AM et al. T cell receptor recognition of a 'super-bulged' major histocompatibility complex class I-bound peptide. Nat Immunol 2005: 6: 1114-22.
24. Sette A, Vitiello A, Reherman B et al. The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes. J Immunol 1994: 153: 5586-92.
25. Noble JA, Valdes AM, Varney MD et al. HLA class I and genetic susceptibility to type 1 diabetes: results from the Type 1 Diabetes Genetics Consortium. Diabetes 2010: 59: 2972-9.
26. Nejentsev S, Howson JM, Walker NM et al. Localization of type 1 diabetes susceptibility to the MHC class I genes HLA-B and HLA-A. Nature 2007: 450: 887-92.
27. Falk K, Rotzschke O, Takiguchi M et al. Peptide motifs of HLA-B38 and B39 molecules. Immunogenetics 1995: 41: 162-4.
28. Zhang QJ, Gavioli R, Klein G, Masucci MG. An HLA-A11-specific motif in nonamer peptides derived from viral and cellular proteins. Proc Natl Acad Sci U S A 1993: 90: 2217-21.
29. Kubo RT, Sette A, Grey HM et al. Definition of specific peptide motifs for four major HLA-A alleles. J Immunol 1994: 152: 3913-24.
30. Maier R, Falk K, Rotzschke O et al. Peptide motifs of HLA-A3, -A24, and -B7 molecules as determined by pool sequencing. Immunogenetics 1994: 40: 306-8.
31. Hickman HD, Luis AD, Buchli R et al. Toward a definition of self: proteomic evaluation of the class I peptide repertoire. J Immunol 2004: 172: 2944-52.
32. Kruger T, Schoor O, Lemmel C et al. Lessons to be learned from primary renal cell carcinomas: novel tumor antigens and HLA ligands for immunotherapy. Cancer Immunol Immunother 2005: 54: 826-36.
33. Hassan C, Kester MG, de Ru AH et al. The human leukocyte antigen-presented ligandome of B lymphocytes. Mol Cell Proteomics 2013: 12: 1829-43.
34. Mommen GP, Meiring HD, Heck AJ, de Jong AP. Mixed-bed ion exchange chromatography employing a salt-free pH gradient for improved sensitivity and compatibility in MudPIT. Anal Chem 2013: 85: 6608-16.
35. Yewdell JW. DRiPs solidify: progress in understanding endogenous MHC class I antigen processing. Trends Immunol 2011: 32: 548-58.
36. Paul S, Weiskopf D, Angelo MA, Sidney J, Peters B, Sette A. HLA class I alleles are associated with peptide-binding repertoires of different size, affinity, and immunogenicity. J Immunol 2013: 191: 5831-9.
37. Machens A, Loliger C, Pichlmeier U, Emskotter T, Busch C, Izbicki JR. Correlation of thymic pathology with HLA in myasthenia gravis. Clin Immunol 1999: 91: 296-301.
38. Loiseau P, Lepage V, Djelal F et al. HLA class I and class II are both associated with the genetic predisposition to primary Sjogren syndrome. Hum Immunol 2001: 62: 725-31.
39. Adamashvili I, Wolf R, Aultman D et al. Soluble HLA-I (s-HLA-I) synthesis in systemic lupus erythematosus. Rheumatol Int 2003: 23: 294-300.
40. Harris JM, Cumming AM, Craddock N, St Clair D, Lendon CL. Human leucocyte antigen-A2 increases risk of Alzheimer's disease but does not affect age of onset in a Scottish population. Neurosci Lett 2000: 294: 37-40.
41. Gerber LH, Murray CL, Perlman SG et al. Human lymphocyte antigens characterizing psoriatic arthritis and its subtypes. J Rheumatol 1982: 9: 703-7.
42. Yamaguchi A, Tsuchiya N, Mitsui H et al. Association of HLA-B39 with HLA-B27-negative ankylosing spondylitis and pauciarticular juvenile rheumatoid arthritis in Japanese patients. Evidence for a role of the peptide-anchoring B pocket. Arthritis Rheum 1995: 38: 1672-7.
43. Gladman DD, Farewell VT. The role of HLA antigens as indicators of disease progression in psoriatic arthritis. Multivariate relative risk model. Arthritis Rheum 1995: 38: 845-50.
44. Keicho N, Ohashi J, Tamiya G et al. Fine localization of a major disease-susceptibility locus for diffuse panbronchiolitis. Am J Hum Genet 2000: 66: 501-7.
45. Singhal SK, Mann SB, Datta U, Panda NK, Gupta AK. Genetic correlation in otosclerosis. Am J Otolaryngol 1999: 20: 102-5.